The DiMethyl-Histone H3 (Lys36) antibody is a key tool for studying histone H3 lysine 36 dimethylation (H3K36me2), a post-translational modification involved in epigenetic regulation. Histone H3K36 methylation plays critical roles in transcription elongation, mRNA splicing, DNA repair, and chromatin structure maintenance. Specifically, H3K36me2 is enriched across gene bodies and correlates with active transcription, serving as a marker for transcribed regions. It also helps suppress cryptic transcription initiation and guides chromatin-modifying enzymes, such as histone deacetylases, to maintain proper gene expression patterns.
This modification is catalyzed by methyltransferases like the NSD family (NSD1. NSD2. NSD3) and SETD1A, while demethylases such as KDM2A/B regulate its removal. Dysregulation of H3K36me2 has been linked to developmental disorders, cancers, and neurological diseases. For instance, mutations in NSD2 or altered H3K36me2 levels are associated with tumorigenesis and poor prognosis in multiple cancers.
The DiMethyl-Histone H3 (Lys36) antibody is widely used in chromatin immunoprecipitation (ChIP), immunofluorescence, and Western blotting to map H3K36me2 distribution, assess its dynamics during cellular processes, or investigate its role in disease. Specificity validation via knockout/knockdown controls is essential, as cross-reactivity with similar histone marks (e.g., H3K36me3) can occur. Researchers rely on this antibody to explore epigenetic mechanisms underlying gene regulation and disease pathology.